Iván Henríquez López1, David Parada2, Pablo Gallardo3, Marina Gascón1, Arnau Besora4, Karla Peña2, Francesc Riu2, Miquel Arquez Pianetta1, Oscar Abuchaibe5, Laura Torres Royò1, Meritxell Arenas1. 1. Radiation Oncology Department, University Hospital of Sant Joan, Institute d'Investigació Sanitaria Pere Virgili (IISPV), Reus, Tarragona, Spain. 2. Pathology Department, University Hospital of Sant Joan, Institute d'Investigació Sanitaria Pere Virgili (IISPV), Reus, Tarragona, Spain. 3. Faculty of Medicine, University Hospital of Sant Joan, Reus, Tarragona, Spain. 4. Bioinformatics, Institute d'Investigació Sanitaria Pere Virgili (IISPV), Reus, Tarragona, Spain. 5. Department of Radiation Oncology, Virgilio Galvis Ramirez Cancer Centre, Bucaramanga, Colombia.
Abstract
OBJECTIVES: Ki-67 is a proliferation marker in prostate cancer. A prognostic RNA signature was developed to characterize prostate cancer aggressiveness. The aim was to evaluate prognostic correlation of CCP and Ki-67 with biochemical failure (BF), and survival in high-risk prostate cancer patients (pts) treated with radiation therapy (RT). METHODS: CCP score and Ki-67 were derived retrospectively from pre-treatment paraffin-embedded prostate cancer tissue of 33 men diagnosed from 2002 to 2006. CCP score was calculated as an average expression of 31 CCP genes. Ki-67 was determined by IHC. Single pathologist evaluated all tissues. Factors associated to failure and survival were analyzed. RESULTS: Median CCP score was 0.9 (-0-1 - 2.6). CCP 0: 1 pt; CCP 1: 19 pts; CCP 2: 13 pts. Median Ki-67 was 8.9. Ki-67 cutpoint was 15.08%. BF and DSM were observed in 21% and 9%. Ki-67 ≥ 15% predicted BF (p = 0.043). With a median follow-up of 8.4 years, 10-year BF, OS, DM and DSM for CCP 1 vs. CCP 2 was 76-71% (p = 0.83), 83-73% (p = 0.86), 89-85% (p = 0.84), and 94-78% (p = 0.66). On univariate, high Ki-67 was correlated with BF (p = 0.013), OS (p = 0.023), DM (p = 0.007), and DSM (p = 0.01). On Cox MVA, high Ki-67 had a BF trend (p = 0.063). High CCP score was not correlated with DSM. CONCLUSIONS: High Ki-67 significantly predicted outcome and provided prognostic information. CCP score may improve accuracy stratification. We did not provide prognostic correlation of CCP and DSM. It should be validated in a larger cohort of pts.
OBJECTIVES: Ki-67 is a proliferation marker in prostate cancer. A prognostic RNA signature was developed to characterize prostate cancer aggressiveness. The aim was to evaluate prognostic correlation of CCP and Ki-67 with biochemical failure (BF), and survival in high-risk prostate cancerpatients (pts) treated with radiation therapy (RT). METHODS: CCP score and Ki-67 were derived retrospectively from pre-treatment paraffin-embedded prostate cancer tissue of 33 men diagnosed from 2002 to 2006. CCP score was calculated as an average expression of 31 CCP genes. Ki-67 was determined by IHC. Single pathologist evaluated all tissues. Factors associated to failure and survival were analyzed. RESULTS: Median CCP score was 0.9 (-0-1 - 2.6). CCP 0: 1 pt; CCP 1: 19 pts; CCP 2: 13 pts. Median Ki-67 was 8.9. Ki-67 cutpoint was 15.08%. BF and DSM were observed in 21% and 9%. Ki-67 ≥ 15% predicted BF (p = 0.043). With a median follow-up of 8.4 years, 10-year BF, OS, DM and DSM for CCP 1 vs. CCP 2 was 76-71% (p = 0.83), 83-73% (p = 0.86), 89-85% (p = 0.84), and 94-78% (p = 0.66). On univariate, high Ki-67 was correlated with BF (p = 0.013), OS (p = 0.023), DM (p = 0.007), and DSM (p = 0.01). On Cox MVA, high Ki-67 had a BF trend (p = 0.063). High CCP score was not correlated with DSM. CONCLUSIONS: High Ki-67 significantly predicted outcome and provided prognostic information. CCP score may improve accuracy stratification. We did not provide prognostic correlation of CCP and DSM. It should be validated in a larger cohort of pts.
Authors: Jack Cuzick; Gregory P Swanson; Gabrielle Fisher; Arthur R Brothman; Daniel M Berney; Julia E Reid; David Mesher; V O Speights; Elzbieta Stankiewicz; Christopher S Foster; Henrik Møller; Peter Scardino; Jorja D Warren; Jimmy Park; Adib Younus; Darl D Flake; Susanne Wagner; Alexander Gutin; Jerry S Lanchbury; Steven Stone Journal: Lancet Oncol Date: 2011-03 Impact factor: 41.316
Authors: Thomas J Sebo; John C Cheville; Darren L Riehle; Christine M Lohse; V Shane Pankratz; Robert P Myers; Michael L Blute; Horst Zincke Journal: Am J Surg Pathol Date: 2002-04 Impact factor: 6.394
Authors: José López Torrecilla; Asunción Hervás; Almudena Zapatero; Antonio Gómez Caamaño; Victor Macías; Ismael Herruzo; Xavier Maldonado; Alfonso Gómez Iturriaga; Francesc Casas; Carmen González San Segundo Journal: Rep Pract Oncol Radiother Date: 2015-05-30
Authors: Matthew R Cooperberg; Jeffry P Simko; Janet E Cowan; Julia E Reid; Azita Djalilvand; Satish Bhatnagar; Alexander Gutin; Jerry S Lanchbury; Gregory P Swanson; Steven Stone; Peter R Carroll Journal: J Clin Oncol Date: 2013-03-04 Impact factor: 44.544
Authors: Rile Li; Kateri Heydon; M Elizabeth Hammond; David J Grignon; Mack Roach; Harvey B Wolkov; Howard M Sandler; William U Shipley; Alan Pollack Journal: Clin Cancer Res Date: 2004-06-15 Impact factor: 12.531
Authors: Alan Pollack; Didier Cowen; Patricia Troncoso; Gunar K Zagars; Andrew C von Eschenbach; Marvin L Meistrich; Timothy McDonnell Journal: Cancer Date: 2003-04-01 Impact factor: 6.860
Authors: Alexander S Parker; Michael G Heckman; Kevin J Wu; Julia E Crook; Tracy W Hilton; Thomas M Pisansky; Johnny R Bernard; Steven E Schild; Li Yan Khor; Elizabeth H Hammond; Alan Pollack; Steven J Buskirk Journal: Int J Radiat Oncol Biol Phys Date: 2009-05-21 Impact factor: 7.038
Authors: J Cuzick; D M Berney; G Fisher; D Mesher; H Møller; J E Reid; M Perry; J Park; A Younus; A Gutin; C S Foster; P Scardino; J S Lanchbury; S Stone Journal: Br J Cancer Date: 2012-02-23 Impact factor: 7.640
Authors: D M Berney; A Gopalan; S Kudahetti; G Fisher; L Ambroisine; C S Foster; V Reuter; J Eastham; H Moller; M W Kattan; W Gerald; C Cooper; P Scardino; J Cuzick Journal: Br J Cancer Date: 2009-03-24 Impact factor: 7.640
Authors: Felipe Couñago; Fernando López-Campos; Ana Aurora Díaz-Gavela; Elena Almagro; Esaú Fenández-Pascual; Iván Henríquez; Rebeca Lozano; Estefanía Linares Espinós; Alfonso Gómez-Iturriaga; Guillermo de Velasco; Luis Miguel Quintana Franco; Ignacio Rodríguez-Melcón; José López-Torrecilla; Daniel E Spratt; Luis Leonardo Guerrero; Juan Ignacio Martínez-Salamanca; Elia Del Cerro Journal: Cancers (Basel) Date: 2020-06-12 Impact factor: 6.639